Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

ubjects identified as responders to Amigal, treatment resulted in increased levels of the target enzyme (a-Gal A), as measured in white blood cells and in the kidney, and reduced levels of the target substrate (GL-3), as measured in renal interstitial capillary cells from kidney biopsies and in urine.

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (a-Gal A). Deficient a-Gal A activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. Amigal is designed to selectively bind to and stabilize a-Gal A, which facilitates proper trafficking of the enzyme to the lysosomes, where it is needed to break down GL-3.

Fabry disease is estimated to affect approximately 5,000 to 10,000 people in the developed world, but recent evidence suggests that the disease may be significantly under-diagnosed. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan designation for Amigal in the United States, and the European Commission has designated Amigal as an orphan medicinal product in the European Union.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay tiered, double digit royalties on net sales of the products. Shire also shares world-wide developmen
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... , March 27, 2015 A new report ... Latin America – Chile , ... are top targets for IVD firms.  The healthcare research ... heavily into IVD strategies for the Latin American continent with ... support globally distributed supply operations. However, the country,s regional economic ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... SAN DIEGO, Nov. 16 CareFusion (NYSE: ... announced a Web-based application that provides hospitals with on-demand ... costs. , The CareFusion Knowledge Portal is a remotely ... information dashboard to review metrics and actionable data directly ...
... Nov. 16 Personalized Pharmaceutical Systems (PPS) today announced ... Viropharma Incorporated. , PPS is a clinical trial ... technology in phenomics to help drug companies identify the ... help patients get the right drug the first time. ...
Cached Medicine Technology:CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms 2CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms 3Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated 2
(Date:3/28/2015)... 2015 Take a bite of warm, ... action. Acids tumble into the stomach, ready to break ... structure lets these acids run amok, triggering a burning ... symptom. More than 60 million Americans have heartburn at ... heartburn starts, and how it can be stopped. , ...
(Date:3/28/2015)... 2015 The California-based leading wig brand ... customer shopping on UniWigs during the Easter Holidays from ... big promotion on April Fools’ Day. , As the ... around the corner. Easter Festival, with religious origins to ... major holiday after Christmas. The best wig provider, UniWigs, ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... medication and reduce risk of ... medication errors, ... move to continually improve patient safety,and staff efficiency, Omnicell, Inc. (Nasdaq: ... facilities, and Grant Regional Health,Center, a leading healthcare provider, today announced ...
... the,appointment of Bryan R. Rogers as President of HCA,s ... Jan. 1, 2008. Rogers replaces Tom,May who recently announced ... will have responsibility for,operations in Nevada, California and Alaska, ... with annual net revenues of,$2.5 billion. He currently ...
... Lead Life Insurance Wholesaling to Company,s Retail Distribution ... Kahal has joined AXA,Equitable as National Sales Manager ... CT. The announcement was made,today by Jamie Shepherdson, ... and annuity wholesale distribution organization. Mr. Kahal,will report ...
... Researchers at the American University of ... that administering a lidocaine lollipop as a single-agent ... endoscopy procedure eliminated the need for sedation in ... in the October issue of Gastrointestinal Endoscopy, the ...
... who couple classroom courses with behind-the-wheel training can significantly ... in the latest issue of The Journal of ... A recent study spearheaded by Yale University,s Richard Marottoli ... underwent eight hours of classroom instruction and two hours ...
... Global Med Technologies(R),Inc. (OTC Bulletin Board: GLOB), ... that it will report its,third quarter results on ... Company will host a conference call at 4:30 ... http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) Conference Call Details: ...
Cached Medicine News:Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 3Health News:Bryan R. Rogers Appointed President of Far West Division 2Health News:David Kahal Joins AXA Equitable as National Sales Manager 2Health News:Patients may have sweet and effective way to prepare for upper GI endoscopy: an anesthetic lollipop 2Health News:Patients may have sweet and effective way to prepare for upper GI endoscopy: an anesthetic lollipop 3Health News:Global Med Technologies(R) Inc. to Announce Third Quarter Results On October 30th - Conference Call to Follow Release 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: